Publications GFPC 2020


Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.


Lung Cancer.2020 Mar 17;143:36-39.


Lien: 10.1016/j.lungcan.2020.03.006


Sanchis-Borja M, Ricordel C, Chiappa AM, Hureaux J, Odier L, Jeannin G, Descourt R, Gervais R, Monnet I, Auliac JB, Chouaïd



First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.


Cancer Med. 2020 Feb 5.


Lien : 10.1002/cam4.2806


Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R.



Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.


J Thorac Oncol 2020 Apr;15(4):628-636


Lien : 10.1016/j.jtho.2019.12.129


Guisier F, Dubos-Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Pérol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O…



Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.


Medicine (Baltimore). 2020 Jan;99(3):e18726


Lien : 10.1097/MD.0000000000018726


Bylicki O, Guisier F, Monnet I, Doubre H, Gervais R, Janicot H, Perol M, Fournel P, Lamy R, Auliac JB, Chouaid C.



Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017). 


Future Oncol. 2020 Feb;16(4):5-10


Lien :  10.2217/fon-2019-0730


Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, Léna H, Chouaïd C, Robinet G.